← Back to Search

Trovax for Renal Cell Carcinoma

Phase 3
Waitlist Available
Research Sponsored by Oxford BioMedica
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.

Eligible Conditions
  • Renal Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TrovaxExperimental Treatment2 Interventions
Group II: PlaceboPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trovax
2006
Completed Phase 3
~740
Standard of care therapy
2006
Completed Phase 3
~1130

Find a Location

Who is running the clinical trial?

SanofiIndustry Sponsor
2,200 Previous Clinical Trials
4,035,673 Total Patients Enrolled
Oxford BioMedicaLead Sponsor
12 Previous Clinical Trials
324 Total Patients Enrolled
~38 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top